LILRB4 as a novel immunotherapeutic target for multiple diseases.
Wang X, Li L, Liu D, Jin Y, Zhao X, Li S, Hou R, Guan Z, Ma W, Zheng J, Lv M, Shi M.
Wang X, et al. Among authors: zheng j.
Biochem Pharmacol. 2025 Jan 20:116762. doi: 10.1016/j.bcp.2025.116762. Online ahead of print.
Biochem Pharmacol. 2025.
PMID: 39842553
Review.